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Abstract
Background—A limitation to efficient lentivirus-mediated airway gene transfer is the lack of 
receptors to commonly used viral envelopes on the luminal surface of airway epithelia. The use of 
viral envelopes with natural tropism to the airway could be useful for overcoming this limitation.
Methods—We investigated influenza hemagglutinin (HA) pseudotyped EIAV-derived lentiviral 
vector-mediated gene transfer to the airway epithelium of adult and newborn mice. For these 
studies high-titer vectors were delivered by intranasal administration. In addition, we tested the 
feasibility of vector re-dosing to the nasal airway.
Results—Delivery of high-titer HA pseudotyped lentiviral vectors by nasal administration to 
newborn mouse pups or adult mice results in efficient transduction of airway epithelial cells in the 
nose, trachea, and lungs. In the nose vector expression was predominant in the respiratory 
epithelium and was not observed in the olfactory epithelium. In the trachea and large airways of 
the lung approximately 46% and 40%, respectively, of surface epithelial cells could be transduced. 
The efficiency of re-dosing to the nasal airway of mice was found to be dependent upon the age of 
the animal when the first dose is administered and the length of time between doses.
Conclusions—A single intranasal dose of concentrated influenza HA-pseudotyped lentiviral 
vector is sufficient for efficient gene transfer to the airways of mice. This is a promising result that 
could lead to the development of effective gene transfer reagents for the treatment of cystic fibrosis 
and other human lung diseases.
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Introduction
Gene transfer has the potential to deliver therapeutic nucleic acids to epithelial cells of the 
airway for the treatment of cystic fibrosis (CF) and other lung diseases. Several studies have 
investigated the use of lentiviruses as gene transfer vehicles for the treatment of CF by 
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delivery of a normal copy of the cystic fibrosis transmembrane conductance regulator 
(CFTR) cDNA to conducting regions of the airways [1-4]. Early studies demonstrated the 
lack of receptors on the apical surface of epithelial cells lining the lumen of the airways for 
viral vectors pseudotyped with the commonly used vesicular stomatitis virus (VSV)-G 
envelope [1, 5-7]. Other studies have found that VSV-G pseudotyped vectors might be useful 
for gene transfer to fetal airways [8-11] or to long-lived alveolar macrophages residing in the 
lung [12, 13].
Recent work has focused on two approaches to increase the efficiency of lentiviral vector 
entry into epithelial cells lining the lumen of the conducting airways. In one approach, 
agents are used to transiently open up tight junctions to allow access of vectors pseudotyped 
with VSV-G to receptors on the basolateral membrane of polarized columnar epithelial cells 
or to basal cells [4, 14]. While it will be important to fully assess the safety of this approach 
[15], this strategy may provide enhanced accessibility to adult airway stem/progenitor cells 
[4].
In a second approach, viral envelopes derived from viruses that are capable of using apical 
membrane receptors on polarized epithelial cells for attachment and entry have been used 
for pseudotyping lentiviral vectors. These include a modified viral envelope spike 
glycoprotein from Ebola virus [16], the GP64 envelope transmembrane protein from 
baculovirus [17, 18], and modified envelope proteins from sendai virus [3]. Although some 
of these studies have shown promise, efficient lentiviral vector gene transfer to the lung 
remains challenging. Efficient vector delivery is critical for a gene transfer approach for 
treating CF since it is believed that vector transduction of 5-10% of the lung epithelium may 
be required for effective treatment [19, 20].
In previous work, we reported studies describing the pseudotyping of lentivirus vectors with 
the hemagglutinin (HA) envelope protein (subtype H7) from a highly pathogenic strain of 
avian influenza virus [21]. An important feature of using the HA envelope glycoprotein of 
influenza virus is that it initiates infection of polarized airway epithelial cells by binding 
sialic acid receptors on the apical membrane surface. Thus, lentiviral vectors pseudotyped 
with influenza HA can access the airway epithelium by delivery via the airway lumen. We 
found that production of vectors was greatly enhanced by co-expressing influenza 
neuraminidase (NA) glycoprotein and the influenza M2 ion channel protein [21]. Using 
cultures of well-differentiated mouse tracheal epithelial cells, delivery of HA-pseudotyped 
vectors to ciliated and non-ciliated cells was observed, with a marked preference for ciliated 
cells [21]. The preference for ciliated cells is advantageous, since those are thought to be 
important targets for the treatment of CF.
In this work, we report further improvements to this system that result in vector preparations 
with sufficient potency to efficiently deliver genes to the airways of adult and neonatal mice 
by intranasal administration. In addition, we explored the feasibility of re-dosing mice with 
the HA-pseudotyped vectors using luciferase imaging to quantify nasal gene expression 
following gene transfer.
Patel et al. Page 2















Human embryonic kidney 293T cells (a kind gift from Dr. Tal Kafri, University of North 
Carolina at Chapel Hill) were maintained in Dulbecco's modified Eagle's medium (DMEM-
H) (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, 
Carlsbad, CA). A clonal cell line that exhibited enhanced transfection efficiency and 
lentiviral vector production was isolated from parental 293T cells. These cells were further 
modified to express human αvß3 integrin to enhance attachment to tissue culture plates [22]. 
A clonal αvß3 integrin-expressing derivative was used for vector production. ED cells are 
normal equine dermal fibroblasts (American Type Culture Collection, CCL-57) and were 
cultured as described previously [23].
Plasmid constructs
The equine infectious anemia virus (EIAV)-based packaging plasmid, pEV53D, was derived 
from pEV53B [23] by removal of a NgoM IV fragment in the vector backbone containing a 
neomycin resistance gene. The LTR self-inactivating (SIN) EIAV gene transfer vector 
SIN6.1-CW [24] was modified by replacing the internal cytomegalovirus (CMV) enhancer/
promoter with a sequence containing the human CMV enhancer/chicken ß-actin (CB) 
promoter. Reporter genes including nuclear-localized lacZ (nlacZ) from pHIT-CMV-nlacZ 
[25], firefly luciferase from the pGL3 basic plasmid (Stratagene, La Jolla, CA), or a dual 
nlacZ-luciferase expression cassette were cloned directly downstream of the internal CB 
promoter of SIN6.1-CBW. To construct the dual nlacZ-luciferase reporter, 18 amino acids 
from the FMDV 2A peptide encoding a stop-carry on translational recoding sequence [26] 
was inserted at the C-terminal Gln amino acid of nlacZ and joined to the Glu amino acid at 
position 2 of luciferase. A linker sequence was placed at both ends of the 2A sequence. The 
HIV-1-based packaging plasmid CMVΔR8.74 [27] was obtained from Dr. Didier Trono 
(École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland). The HIV-1 based gene 
transfer vector, LV-CB-nlacZ, was created by replacing the internal expression cassette in 
pTK642 [28] with the CB-nlacZ expression cassette in the EIAV-CB-nlacZ vector described 
above. The plasmid expressing the vesicular stomatitis virus (VSV) envelope glycoprotein, 
pCI-VSV-G, has been described previously [5]. The influenza virus M2 expression vector 
pCI-M2 was derived from pCB6-M2 [21] by subcloning the M2 cDNA sequence into the 
pCI vector (Promega Corporation, Madison WI). The pNAHA plasmid expression vector 
encoding influenza neuraminidase (NA) and influenza hemagglutinin (HA) was constructed 
by cloning a PCR amplified DNA fragment containing the influenza HA (subtype H7) 
cDNA from (A/FPV/Rostock/8/34) [29] into the SgrAI-XhoI site of multiple cloning site 2 
and a PCR fragment containing the influenza NA (subtype N1) cDNA from A/Puerto Rico/
8/34 [21] into the MluI-AvrII site of multiple cloning site 1 of the pVITRO2 expression 
vector (InvivoGen, San Diego, CA). For expression of human influenza HA (subtype H3), 
PCR amplified DNA product encoding the HA cDNA from A/England/26/99 [30] was 
cloned into the MluI-AvrII site of the pVITRO2 expression vector.
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Vector production and titering
Recombinant EIAV-based lentiviral vector stocks were generated by transient transfection of 
293T-based TAB22 cells as previously described [5]. Briefly, 1.93×107 TAB22 cells were 
plated onto 15-cm tissue culture dishes containing DMEM-H medium with 10% FBS 20 h 
prior to transfection. The next day, the medium was changed to 20 mL DMEM-H containing 
6% FBS and each 15-cm culture dish was transfected by the standard calcium phosphate 
method with 50 μg gene transfer plasmid, 50 μg pEV53D, 5 μg pCI-M2, and 30 μg pNAHA. 
After 24 h cultures were replenished with DMEM-H medium containing 2% FBS and 10 
mM sodium butyrate and after a further 24 h incubation cell supernatant containing viral 
vectors was harvested. Virus preparations were clarified by low speed centrifugation (100 g, 
10 min) and filtered through 0.2 μm PES membranes and used for transduction directly or 
subjected to high speed centrifugation at 5000 g (Beckman Avanti J-E centrifuge, JS-5.3 
rotor) for 21 h at 8°C. Virus pellets were suspended in vector formulation buffer (5 mM 
Hepes (pH 7.4), 37 mM NaCl and 40 mM lactose) and stored at −80°C.
Recombinant lentiviral vector stocks were titered on 293T cells. Cells were plated at 105 
cells/well in 12-well dishes 18 h prior to infection. Serial dilutions of viral vector stocks 
were applied to cells for 2 h before replenishing with fresh growth medium. For vectors 
encoding lacZ, the percentage of transduced cells was determined using a hemocytometer-
based assay as described previously [23]. For vectors encoding luciferase, a PCR assay was 
used to quantify vector proviral DNA in the chromosomal DNA of infected cells [31]. 
Briefly, after infection, cells were passaged twice and washed extensively with PBS to make 
sure all contaminating plasmid DNA was removed. Genomic DNA from these cells was 
harvested with the DNeasy Kit (Qiagen Corporation, Valencia, CA). The number of 
integrated vector copies was determined by Light-Cycler PCR using the FastStart DNA 
Master SYBR Green kit (Roche, Indianapolis, IN) and primers for a region of the WPRE 
sequence: 5’-CGCTGCTTTAATGCCTTTGT-3’ and 5’-ACAACACCACGGAATTGTCA-
‘3. The results were compared to a standard from cells infected with a known copy number 
of vector and the infectious units (IU)/ml of the original vector stock was determined.
In vivo delivery of lentiviral vectors to mice and luciferase imaging
All procedures using animals were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill, and were conducted in 
accordance with policies for the ethical treatment of animals established by the National 
Institutes of Health.
For lentiviral vector administration to newborn (1-2 day old) mice, the vector (6 μL) was 
administered drop-wise to the left nostril of isoflurane-anesthetized CD1 mice (Charles 
River Laboratories, Wilmington, MA). Similarly, isoflurane-anesthetized 4-week-old young 
adult CD1 or BALB/c mice (Charles River Laboratories, Wilmington, MA) were dosed 
intranasally with a 20-40 μL volume of vector. Isoflurane anesthesia (2.5% isoflurane/1.5L 
oxygen per minute) and dosing of animals was carried out in a vented biological safety 
cabinet. For live animal imaging of nasal luciferase expression, mice were anesthetized with 
isoflurane and D-luciferin (Gold Biotechnology, St. Louis, MO) substrate (20 μL of 25 
mg/mL D-luciferin in PBS) was delivered by intranasal administration [32]. Mice were 
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imaged using the IVIS Lumina optical imaging system (Caliper Life Sciences, Hopkinton, 
MA) and images of luciferase activity were collected using a CCD camera interfaced to a 
computer.
X-Gal histochemistry
For processing of mouse lungs for X-Gal staining of cryosections, lungs were inflated 
through the trachea with OCT embedding as described previously [33] and frozen tissue was 
sectioned at 10 μm. Sections were fixed with 0.5% glutaraldehyde in PBS, washed with 
PBS, and stained for 4 h at 37°C with X-Gal Solution (1 mg/mL X-Gal in PBS (pH 7.0) 
containing 20 mM potassium ferricyanide, 20 mM potassium ferrocyanide, and 1 mM 
MgCl2). For X-Gal staining of intact tissue, lungs were inflated with and submerged in 0.5% 
glutaraldehyde for 2 h at 4°C, washed in PBS/1 mM MgCl2, and stained in X-Gal Solution 
for 16 h as described [33]. Tissues were washed in water and embedded in paraffin for 
preparation of 8 μm sections. For analysis of nlacZ expression in the nasal cavity, heads 
were processed for X-Gal staining and decalcification prior to sectioning as described [6].
Neutralization of vector infectivity by mouse sera
Blood was drawn from CD-1 mice before each vector instillation and then again when the 
mice were sacrificed. Serum samples were heat inactivated for 30 min at 56°C to destroy 
complement. To test for neutralization of infectivity, serial two-fold dilutions of sera from 
initial 1:4 dilutions were incubated with approximately 20,000 RLU of pseudotyped EIAV-
CMV-luciferase vectors for 1 h at 37°C and inoculated in triplicate onto ED cells seeded the 
previous day in 96-well plates at 104 cells per well [34]. Cells were assayed 72 h post-
infection for luciferase activity using the SteadyGlo substrate (Promega Corporation, 
Madison WI) and the signal was read with a Veritas plate-reader luminometer (Turner 
Biosystems, Sunnyvale, CA).
Results
Production of influenza HA pseudotyped lentiviral vectors
Previously, we reported that optimal production of influenza virus HA (subtype H7) 
pseudotyped lentiviral vectors based on equine infectious anemia virus (EIAV) or HIV-1 
required co-expression of influenza neuraminidase (NA) and influenza M2 proteins [21]. In 
order to simplify vector production, cDNAs for the expression of HA and NA were co-
expressed from a single plasmid thus reducing the number of plasmids required for transient 
production from five to four (Figure 1). The reduction in the number of plasmids resulted in 
approximately a 3-fold increase in vector production, such that non-concentrated vector 
preparations with titers up to 106 infectious units/mL could be obtained. Vector production 
of HA-pseudotyped EIAV-CB-nlacZ could be scaled up to 1000 mL without loss in expected 
yield. Following collection of the culture supernatant, vector preparations were concentrated 
up to 3000-fold resulting in concentrated vector stocks with titers up to about 109 infectious 
units/mL (average titer = 7.5×108 IU/ml, range = 2.6×108-1.4x109 IU/mL; n=7).
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Transduction of mouse airways by nasal delivery of HA-pseudotyped lentiviral vectors
To evaluate vector expression following delivery to mouse airways, a single administration 
of HA-pseudotyped EIAV-CB-nLacZ (2×107 IU, unless indicated otherwise) was delivered 
in a volume of 30 μL to 4-week-old CD-1 mice by intranasal inhalation. Animals were 
sacrificed three weeks after gene transfer and the airways were processed for staining with 
X-Gal for detection of ß-galactosidase activity expressed from the nuclear-localized lacZ 
reporter gene (nlacZ). In some experiments, intact glutaraldehyde-fixed tissues were stained 
directly. In other experiments, cryosections of lungs and trachea were fixed and stained with 
X-Gal.
To locate EIAV-CB-nLacZ expression in the nasal passage, the nasal cavity was fixed, 
stained with X-Gal and de-calcified. Coronal sections were prepared and sampled for 
microscopic examination. Expression of nlacZ was detected in surface epithelial cells of the 
nasal airway (Figure 2). Nasal lacZ expression was commonly found in ciliated cells in the 
respiratory epithelium lining the ventral region of the nasal septum, although expression 
could be observed elsewhere in the nasal cavity (Figure 2A,C). In contrast, lacZ expression 
was absent in surface sustentacular cells and olfactory sensory neurons of the olfactory 
epithelium from the dorsal region of the nasal septum (Figure 2B). These results suggest a 
specificity of this HA-pseudotyped lentivirus vector for expression in nasal respiratory 
epithelium.
Because the respiratory epithelium in the nasopharynx is useful for differentiating the 
bioelectric properties between CF mice and non-CF mice [35], more distal sections of the 
nasal passage were examined for nlacZ expression. As shown in Figure 2D, significant 
EIAV-CB-nlacZ expression could be observed in nasopharyngeal epithelia. Thus, the 
nasopharynx is a potential target for assessing the normalization of bioelectric activity in CF 
mice by treatment with HA-pseudotyped vectors encoding CFTR cDNA
Lentiviral vector gene expression in adult trachea and tracheal submucosal glands
X-Gal stained cryosections of the trachea readily revealed EIAV-CB-nLacZ expression 
(Figure 3B,D) in surface epithelium. No appreciable X-Gal staining was detected in sham-
infected control mice (Figure 3A,C). To estimate the efficiency of gene transfer, the 
percentage of X-Gal stained cells on the surface of the tracheal epithelium was determined 
by comparing the number of X-Gal stained cells to total surface cells in X-Gal stained 
cryosections. It was found that 45.7% ± 6.3% (mean ± SEM, n=4) of the surface epithelial 
cells were transduced.
In the proximal trachea, expression was also observed in submucosal glands below the 
airway surface (Figure 3E,F). While the percentage of transduced gland cells was estimated 
to be at least 10-fold lower than tracheal surface expression, submucosal gland expression of 
nlacZ was not rare. From a screen of mice in the experiment described in Figure 3, 
submucosal gland expression was observed in four of four CD1 mice and three of four 
BALB/c mice.
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Lentiviral vector gene expression in adult mouse lung
Evidence of X-Gal staining was evident in whole lungs of mice dosed with the EIAV-CB-
nLacZ vector (Figure 4B-D) but not in sham-infected control mice (Figure 4A). Staining 
could be observed throughout the airways including distal regions of branching airway 
extending to terminal bronchioles (Figure 4D). In cross sections of dissected mouse lungs, 
X-Gal stained cells could be detected in small and large airways of all five mouse lobes 
(Figure 5A-E). Higher magnification of X-Gal stained cryosections confirmed that 
expression was localized to surface cells in the lung epithelium (Figure 6A,B). In contrast, 
there was no comparable X-Gal staining in lungs from negative control mice (Figure 5F and 
Figure 6D). To estimate the efficiency of gene transfer, the percentage of X-Gal stained cells 
in the large airways was determined in ten 300-400 μm representative segments from stained 
cryosections. It was found that 40.3% ± 11.9% (mean ± SEM, n=4) of the surface epithelial 
cells were transduced in large airways.
To determine if other lentivirus-based vectors could be used for efficient gene transfer to the 
lung, we tested a HIV-1-based vector encoding an analogous CB-nlacZ expression cassette. 
It was found that nasal delivery of 20 μL (2×107 IU) of the HA pseudotyped HIV-1 based 
nlacZ vector could also efficiently transduce the lung epithelium of CD1 mice (Figure 6C). 
Thus, the HA pseudotyping system that is described in this report may also be useful for 
gene transfer to mouse airways by non-EIAV-based lentiviral vectors.
Delivery of influenza HA-pseudotyped lentivirus vectors to neonatal mouse airways
Because pathogenesis of CF lung disease may become apparent shortly after birth [36], we 
tested the ability of HA-pseudotyped EIAV lentiviral vectors to transfer genes to neonatal 
mouse airways. Vectors were delivered by dropwise instillation into the left nostril of 
isoflurane-anesthetized neonates (1-2 days old). Because the volume that could be instilled 
safely to newborn mice was limited, a preliminary pilot experiment established that a 6 μL 
delivery volume was well tolerated by mouse pups. Sequential (up to three) 6 μL doses 
could be given to newborns provided that mice were allowed to wake and recover from 
anesthesia between each dose. In these experiments, a dual nlacZ-luciferase expression 
vector was used, in which expression of nlacZ and firefly luciferase were linked by a viral 
2A “stop-carry on” peptide sequence [26]. At various times after the mice were dosed with 
the vector, luciferin was instilled intranasally and luciferase activity was measured (Figure 
7A). In parallel control experiments, the same lot of vector (20 μL) was delivered to 4-week-
old mice. Luminescence from luciferase activity was detected at the earliest time point, 72 h 
after transduction, in both neonatal and adult mice (Figure 7B). The magnitude of nasal 
luciferase expression in neonatal compared to adult mice was similar, suggesting that host 
factors required for transduction by this HA-pseudotyped vector are in place in both age 
groups. With adult mice, nasal gene expression following a single dose of 20 μL was half 
maximal at day 3, reaching a plateau in expression by day 7. In contrast, nasal gene 
expression in neonatal mice reached a plateau by day 3 (Figure 7B).
Lentiviral vector lacZ expression in neonatal mouse nose and lung
The use of a dual nlacZ-luciferase expression cassette allowed for histochemical analysis of 
nlacZ gene expression in the nose and more distal airways. Following the 10-day luciferase 
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measurement (Figure 7B), neonatal mice were euthanized and frozen sections of lungs were 
fixed and stained with X-Gal. Sections were also prepared from nasal airways from X-Gal 
stained and de-calcified heads. Nasal expression was observed mainly on the epithelial 
surface of the nasal septum, although expression could also be observed in other regions of 
the nasal epithelium (Figure 7C,D). Similar to adult mice, the lung epithelium of neonatal 
mice showed wide spread X-Gal staining (Figure 7E). As assessed by image analysis, no 
significant difference in nasal luciferase gene expression was noted for the three doses (6, 
12, and 18 μL) that were administered to neonates Figure 7B). This contrasted to 
measurements made in the lung where there appeared to be a dose-response relationship 
between vector dose and the relative number of cells transduced in the airway epithelium 
(Figure 7F). At the highest dose (18 μL), approximately 18% (n= 2) of the epithelial surface 
of the large airway in the left lobe of neonatal mice was transduced with the HA-
pseudotyped EIAV-CB-nlacZ-luciferase vector.
From these studies we conclude that nasal vector gene expression can be detected within 
three days following gene transfer to 1-2 day old neonates and it is possible to obtain 
efficient delivery to the lungs of neonatal mouse airways by intranasal inhalation.
Effect of vector re-administration to mice nasal airway
For treatment of many genetic diseases using a gene transfer approach, it will be important 
to re-administer the vector if expression of the vector wanes due to cell turnover or other 
mechanisms. A possible complication of re-administering lentiviral vectors to adult animals 
with a mature immune system could be limited gene transfer by the second dose due to the 
generation of a neutralizing antibody response against the vector following the first dose. By 
contrast, if the first dose is given to a neonate whose developing immune system is still 
immature, it is possible that the efficiency of the second dose would be similar to the 
efficiency of dosing a naïve animal [37]. We performed a series of experiments with CD-1 
mice to determine if the host immune response against HA-pseudotyped lentiviral vectors 
would prevent or tolerate a subsequent administration of a second dose of vector containing 
the same pseudotype.
In an initial experiment, 4 week old mice were dosed with 2.4 × 107 IU influenza HA 
pseudotyped EIAV-CB-nlacZ by nasal inhalation. Either three weeks or three months later, 
these mice or parallel naive mice were challenged by nasal administration with 7 × 106 IU 
EIAV-CB-luciferase pseudotyped with HA of the same H7 subtype. Note that the challenge 
vector contained a different transgene than the vector administered in the first dose, as we 
wanted to eliminate the effect of pre-existing immunity against transgene expression. The 
kinetic profile of nasal luciferase expression is shown in Figure 8. Mice previously dosed 
with vector and re-dosed at three weeks with EIAV-CB-luciferase had 10-20% of the 
expression levels of control mice receiving a single dose of vector (Figure 8A). In contrast, 
when the time period between doses was increased from 3 weeks to three months, mice 
receiving two doses had 30-40% of the expression levels compared to control mice that 
received a single dose (Figure 8B). These results suggest that there is a decrease in gene 
transfer efficiency upon re-administration of vectors with the same HA envelope pseudotype, 
however, the host response resulting in lowered gene transfer efficiency wanes with time.
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This experiment was repeated, except that the initial dose of HA pseudotyped EIAV-CB-lacZ 
was administered to 1-2 day old newborn mice. The mice were then challenged either 3 
weeks (Figure 8C) or 12 weeks later (Figure 8D) with HA pseudotyped EIAV-CB-luciferase. 
In neither case was there a decline in gene expression efficiency compared to control naïve 
mice.
Detection of a serum neutralizing response in treated adult mice
In the experiments involving re-dosing of adult mice (Figure 8A, B), it was not clear if 
reduced gene transfer efficiency was due to an adaptive immune response to the vector or 
due to other mechanisms. To ascertain whether neutralizing antibodies had been generated in 
4 week old mice administered with the first vector, sera were collected and tested in a vector 
neutralization assay. The results in Figure 9A indicate that sera from mice dosed with HA 
pseudotyped EIAV vectors effectively inhibited gene transfer of HA pseudotyped vectors 
with the same H7 subtype in a neutralization assay. The calculated anti-H7 HA IC90 serum 
titer (serum dilution that yields the inhibitory concentration required for 90% inhibition) for 
Mouse 1 was found to be 85, while Mouse 2 had an IC90 of 14. A commercial polyclonal 
antibody specific for H7 HA influenza virus was used as a positive control and had a strong 
neutralizing activity in this assay. Pre-immune sera or sera from non-transduced littermates 
did not show neutralizing activity.
To determine the specificity of the neutralizing response, sera from mice dosed with the H7 
HA pseudotype or a commercial anti-H7 antiserum were tested for their ability to inhibit 
transduction by a lentiviral vector pseudotyped with HA from a different serological 
influenza subtype, H3. As shown in Figure 9B, the commercial H7 HA anti-serum or sera 
from mice dosed with H7 HA EIAV vectors were not effective at inhibiting infectivity of an 
EIAV vector with a human influenza H3 HA pseudotype. In addition, VSV-G pseudotyped 
vectors were also not inhibited by sera from animals dosed with H7 HA pseudotyped EIAV 
vectors (unpublished data). These results are consistent with the generation of a specific 
immune response in mice dosed with H7 HA pseudotyped EIAV vectors. These results also 
suggest that the HA is the major neutralizing determinant of HA pseudotyped EIAV vectors 
since it was the only variable in the production of the two different influenza HA 
pseudotypes. All other vector proteins, including the influenza neuraminidase (NA) and M2 
proteins were common to the production of both H7 and H3 pseudotypes.
Discussion
Pseudotyping lentiviruses with influenza virus HA is challenging in that the functions of 
influenza virus NA and influenza M2 may be required for optimal vector production. We 
found that co-expressing NA and HA from the same plasmid led to more efficient vector 
production than we described previously [21] enabling the preparation of concentrated 
vector preparations with titers approaching 109 IU/ml.
A single dose of concentrated influenza HA-pseudotyped EIAV-based lentiviral vectors 
delivered by nasal administration to mice could efficiently transduce the respiratory 
epithelium of the nose, trachea, and all five lobes of the mouse lung. The efficiency of gene 
transfer to the lung (18%, neonates, 40% adults) was in excess of the 5-10% threshold 
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thought to be important to provide benefit in a treatment strategy for CF lung disease [19, 
20]. Thus, if this vector system could be adapted for treatment of human CF, it is possible 
that a lentivirus-based approach could be used to effectively treat aspects of this lung 
disease. While it is generally accepted that innate barriers including mucus, the glycocalyx 
and other components in the airway lumen have evolved to prevent invasion by micro-
organisms, the results of the studies reported here are consistent with the hypothesis that 
exploiting the features of relatively successful respiratory viruses can be used to generate 
effective gene transfer vectors that can overcome innate barriers for efficient lung gene 
transfer.
In the nasal epithelium of mice, transduction by the HA pseudotyped EIAV-CB-nlacZ vector 
appeared to be limited to respiratory epithelium. Transduction of significant olfactory 
epithelium in the nose was not observed. Respiratory epithelium of the nasopharynx was 
also transduced, which might prove to be useful in assays to assess the normalization of 
bioelectric properties in CF mice by lentiviral vectors encoding CFTR cDNA [35].
While a previous study has shown that tracheal submucosal glands can be transduced by 
vectors following intratracheal injection [38], the data reported in this study suggests that 
nasal delivery can also lead to transduction of submucosal glands, albeit at a lower rate than 
the surface epithelium. Because ciliated epithelial cells within submucosal glands express 
CFTR and are thought to be an important target for treatment of cystic fibrosis [39], it is 
possible that the ability of influenza HA pseudotypes to target these cells could be exploited 
in treatment strategies.
The treatment of CF using a gene transfer approach requires expression of CFTR over the 
lifetime of the patient. While previous studies using lentivirus-based gene transfer vector 
have shown long-term nasal gene expression [3, 4, 17, 18], we considered that normal cell 
turnover might require repeat vector administration. A possible complication of vector re-
administration could be limited gene transfer due to the generation of a neutralizing immune 
response against the vector. We found that application of a second dose of HA-pseudotyped 
vectors is feasible, with the efficiency of gene transfer of the second dose dependent upon 
the age of mice receiving the first dose and the time interval between doses. Previous 
lentivirus-based gene transfer studies using other viral envelope pseudotypes, including a 
baculovirus GP64 pseudotyped feline immunodeficiency virus vector [40] and a sendai 
F/HN pseudotyped simian immunodeficiency virus based vector [3] have also shown the 
feasibility of repeat dosing of the nasal airway of mice using the same vector pseudotype.
Because we used a HA from an avian influenza virus (A/Fowl Plague Virus/Rostock/8/34) 
that has not adapted to replicate in human cells, it is likely that further modification of the 
HA pseudotyping system would be beneficial in order to obtain optimal gene transfer 
efficiency to human airways for treatment of cystic fibrosis. The avian influenza HA used 
here is known to bind preferentially to terminal sialic acids attached with α-(2,3) linkages. 
Adaptation of avian influenza virus to replicate in the upper human respiratory tract 
commonly includes changes in the sialic acid receptor binding domain of HA to recognize 
sialic acids attached with α-(2,6) linkages that are abundant in the human airway [41-43]. 
Thus, the use of HA from human influenza virus strains or the modification of avian 
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influenza virus HA to utilize sialic acid receptors common in the human respiratory tract 
[44-47] may be required to optimize the efficiency of influenza HA pseudotyped lentivirus-
based vector delivery for human clinical studies.
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Plasmid constructs for pseudotyping lentiviral vectors with influenza virus envelope 
proteins. The EIAV SIN6.1CB-W gene transfer vector contains a CMV enhancer/promoter 
fused to the R and U5 domains of the EIAV long terminal repeat (LTR) sequence, the viral 
Rev Responsive Element (RRE), RNA encapsidation sequence (Ψ), an internal hybrid CMV 
enhancer/chicken ß-actin promoter driving the nuclear-localized E. coli ß-galactosidase 
(nlacZ) or firefly luciferase (Luc) genes, the woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE), and a 3’ self-inactivating (SIN) LTR sequence. The gag-pol-rev 
expression vector (pEV53B) is used to express the EIAV Gag, Pol, and Rev proteins. 5’ and 
3’ splice sites are indicated (SD and SA). The pCI-M2 vector is used to express the 
influenza virus M2 ion channel. The pNAHA vector is used for expression of influenza virus 
neuraminidase (NA) and influenza virus hemagglutinin (HA) genes. The plasmid backbones 
are not shown. Other abbreviations: S/hFerL, hybrid SV40 enhancer/human ferritin light 
chain promoter; C/hFerH, hybrid CMV enhancer/human ferritin heavy chain promoter; 
FMDV IRES, Foot and mouth disease virus internal ribosome entry site sequence; hph, 
hygromycin B phosphotransferase gene; pA, polyadenylation signal.
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Expression of influenza HA pseudotyped EIAV-CB-nlacZ vector in nasal cavity of adult 
mice. Three weeks following vector nasal administration to the right nostril of four week old 
mice, mice were analyzed for expression of nlacZ. (A) Coronal section from X-Gal stained 
nasal cavity. Vector nlacZ expression appears as blue staining. S denotes the nasal septum. 
The upper and lower boxed regions of the nasal septum were magnified (x20) and shown in 
panels (B) and (C), respectively. (B) The transition zone between the olfactory epithelium 
(oe) and respiratory epithelium along the nasal septum. (C) Region of respiratory epithelium 
(re) from the nasal septum, which is efficiently transduced by HA pseudotyped lentiviral 
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vectors. (D) Section from distal nasal airway showing EIAV-CB-nlacZ expression in 
nasopharyngeal epithelium. NP, nasopharyngeal cavity.
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Expression of influenza HA pseudotyped EIAV-CB-nlacZ vector in trachea and tracheal 
submucosal glands of adult mice following intranasal delivery. Three weeks following gene 
delivery to the right nostril of four week old CD1 (Panels A-E) or BALB/c mice (Panel F), 
mice were analyzed for expression of nlacZ. Panels (A) and (B) show low power (x4) 
magnification of X-Gal stained longitudinal cryosections of a non-transduced control mouse 
trachea and EIAV-CB-nlacZ transduced mouse trachea, respectively. Panels (C) and (D) are 
higher magnification (x10) histologic sections of X-Gal stained control trachea and EIAV-
CB-nlac transduced mouse trachea, respectively (E) X-Gal stained cryosection from 
proximal region of trachea from a CD1 mouse transduced with EIAV-CB-nlac. (F) X-Gal 
stained cryosection from proximal region of trachea from a BALB/c mouse transduced with 
EIAV-CB-nlac. The images in (E) and (F) show X-Gal stained cells within submucosal 
glands below the tracheal surface. Sections were counterstained with nuclear fast red.
Patel et al. Page 17














Expression of influenza HA-pseudotyped EIAV-CB-nlacZ in whole mouse lung following 
intranasal delivery. X-Gal stained whole lungs from (A) control CD1 mouse and (B,C) mice 
dosed with HA-pseudotyped EIAV-CB-nlacZ vector. The close-up (D) of an EIAV-CB-nlacZ 
dosed animal indicates staining consistent with gene transfer to terminal bronchiolar regions.
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Gene transfer to all lobes of mouse lung following intranasal delivery of HA-pseudotyped 
EIAV-CB-nlacZ vector. Panels show scanned images of longitudinal sections of dissected 
mouse lung lobes from a single CD1 mouse counterstained with nuclear fast red. The whole 
lung was inflated and stained with X-Gal prior to sectioning. Mouse lobes include: (A) left 
lobe; (B) apical lobe; (C) azygous lobe; (D) cardiac lobe; and (E) diaphramatic lobe. Panel 
(F) shows the left lobe from a sham-infected control animal stained with X-Gal and 
counterstained with nuclear fast red (original magnification, x4).
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X-Gal stained cryosections from lungs of CD1 mice transduced with HA-pseudotyped 
lentiviral vectors encoding nlacZ. (A) Distal region of bronchi from mouse transduced with 
EIAV-CB-nlacZ. (B) Bronchiole from mouse transduced with EIAV-CB-nlacZ. (C) 
Bronchioles from CD1 mouse transduced with HIV-1 based vector LV-CB-nlacZ. The 
expression cassette is identical to that used in EIAV-CB-nlacZ. (D) Bronchiole from sham-
infected control mouse. Original magnification (x20) except for panel C (x10).
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Nasal delivery of influenza HA-pseudotyped EIAV-CB-nlacZ-luciferase vector to neonatal 
mice. (A) Luciferase imaging of young mouse pups. Three days after intranasal delivery of a 
dual EIAV-CB-nlacZ-luciferase vector to 1-day-old neonatal mice or young adult (4 week 
old) mice, luciferin was administered intranasally and luciferase catalyzed bioluminescence 
was captured using the Xenogen optical imaging system. Bar in lower left of each panel 
represents 15 mm. (B) Kinetics of luciferase expression in the nose of neonatal and adult 
mice. The vector was delivered by nasal inhalation of 6, 12, or 18 μL (total volume) to 
newborn mice (1-2 days old) or 20 μL to 4-week-old young adult mice. The titer of the 
vector was 2×108 IU/mL. For adult mice, the vector was delivered as a single bolus. For 
neonatal mice the vector was delivered in 6 μL doses, allowing the pups to recover 
completely between consecutive doses. At various times after gene transfer, luciferin was 
administered intra-nasally and the luciferase activity was measured. Non-transduced control 
animals were dosed with luciferin and imaged in parallel. Results are expressed as mean 
luciferase activity (photons/sec/cm2) ± SEM (n=2 mice per data point (neonates) or n=6 
mice per data point (adults). (C) Low power image of X-Gal stained coronal nose section 
counterstained with nuclear fast red. (D) Magnified boxed region from panel C. The heaviest 
stained region is along the surface of the nasal septum. (E) Cryosections from the left lung 
lobe of neonatal mouse (6 μL dose) were fixed with glutaraldehyde and stained with X-Gal. 
Upper left panel shows X-Gal stained section from sham-infected control mouse. (F) 
Quantification of gene transfer to neonatal lung. The percentage of X-Gal stained blue cells 
per total number of surface cells from the large airway in the left lung lobe was determined 
using image analysis. Results are expressed as mean percentage (n=2 mice per data point).
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Repeat administration of HA-pseudotyped EIAV vectors to nasal epithelium of mice. 
‘Control’ mice received a single dose of EIAV-CB-luciferase (7×106 IU). ‘Re-dose’ mice 
received EIAV-CB-nlacZ (2.8×107 IU) at either four weeks of age (panels A and B) or 1-2 
days after birth (panels C and D) followed either 3 weeks (panels A and C) or 3 months 
(panels B and D) later with EIAV-CB luciferase (7×106 IU). ‘Control’ mice and ‘re-dose’ 
mice were dosed with the EIAV-CB-luciferase vector on the same day. Luciferase expression 
was monitored using a Xenogen CCD system after nasal luciferin administration. Each point 
represents the mean photons/sec/cm2 ± SEM, n=4 for each group after subtracting out values 
from negative control mice. Negative control mice (undosed, age-matched) were imaged in 
parallel in each imaging session and had an average signal of less than 104 photons/sec/cm2.
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Detection of influenza subtype H7 HA-specific neutralizing activity in sera of mice 
transduced with influenza HA-pseudotyped EIAV-nlacZ vectors. The neutralization of 
infectivity of EIAV-luciferase vectors pseudotyped with influenza subtype H7 HA (left 
panel) or human influenza subtype H3 HA (right panel) was measured using dilutions of 
antisera ranging between 1:4 and 1:512. H3 or H7 pseudotypes were pre-incubated with 
anti-sera for 1 h at 37°C prior to transducing ED cells. At 48 h post infection luciferase 
activity was determined. Results are expressed as the mean luminescence measured in 
relative light units (RLU) ± standard error of one experiment run in triplicate. Source of 
antisera: Mouse 1 and Mouse 2, heat-inactivated sera from mice that received a single dose 
of EIAV-CB-nlacZ. Blood was harvested when the animals were sacrificed at 3 weeks after 
gene transfer; anti-H7, commercial antiserum raised in sheep to H7 influenza (NIBSC, 
Hertfordshire, UK); control serum, heat inactivated serum from sham-infected control 
mouse; no serum control, no virus cell background.
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